[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100556147":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":32,"centralContacts":37,"locations":48,"responsibleParty":63,"collaborators":31,"id":65,"slug":66,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":67,"sex":73,"minAge":74,"maxAge":31,"enrollmentInfo":75,"targetDuration":31,"studyType":78,"phases":79,"briefSummary":81,"conditions":82,"keywords":85,"overallStatus":95,"whyStopped":31,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":100,"completionDateStruct":101,"leadSponsor":103,"locationsCount":104},{"fullName":5,"class":6},"Instituto Nacional de Cardiologia Ignacio Chavez","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Riboside (RN) arm","EXPERIMENTAL","NAD Riboside 2000 mg by oral intake at enrollment 24hrs prior surgery, 3000mg prior undergoing surgery with NG tube, 3000mg 12 hrs post-surgery with NG tube and 2000mg 24 hrs after intervention by oral intake.",[13],"Dietary Supplement: Nicotinamide riboside",{"label":15,"type":16,"description":11,"interventionNames":17},"Placebo arm","PLACEBO_COMPARATOR",[18],"Other: Placebo",[20,27],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DIETARY_SUPPLEMENT","Nicotinamide riboside","We will recruit the participant 24 hrs prior intervention, once the participant decides to enroll, we will administer by oral intake the supplement or placebo due to the result at randomizer.org.\n\nThe first NAD Riboside arm will be administered by oral intake with 2000 mg at enrollment, then we will administer 3000mg prior undergoing surgery with NG tube, 3000mg 12 hrs post-surgery with NG tube and 2000mg by oral intake 24 hrs after intervention. All the administrations with NG tube will be flushed with 0.9% saline solution.",[9],[26],"NADH Riboside",{"type":6,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"Placebo","We will recruit the participant 24 hrs prior intervention, once the participant decides to enroll, we will administer by oral intake the supplement or placebo due to the result at randomizer.org.\n\nThe first dose of placebo arm will be administered by oral intake with 2000 mg at enrollment, then we will administer 3000mg prior undergoing surgery with NG tube, 3000mg 12 hrs post-surgery with NG tube and 2000mg by oral intake 24 hrs after intervention. All the administrations with NG tube will be flushed with 0.9% saline solution.",[15],null,[33],{"name":34,"affiliation":35,"role":36},"Magdalena Madero","Instituto Nacional de Cardiología. Ignacio Chávez","PRINCIPAL_INVESTIGATOR",[38,44],{"name":39,"role":40,"phone":41,"phoneExt":42,"email":43},"Magdalena Madero, MD","CONTACT","015555732911","1273","madero.magdalena@gmail.com",{"name":45,"role":40,"phone":46,"phoneExt":42,"email":47},"Ana K. Fernandez, MD","5611133180","anakaren.fyepez@gmail.com",[49],{"facility":50,"status":31,"city":51,"state":31,"zip":52,"country":53,"countryCode":54,"cosmosGeoPoint":55,"geoPoint":60,"contacts":61},"Insituto Nacional de Cardiología Ignacio Chávez","México","14080","Mexico","MX",{"type":56,"coordinates":57},"Point",[58,59],-108.15213,31.00435,{"lat":59,"lon":58},[62],{"name":39,"role":40,"phone":41,"phoneExt":42,"email":43},{"type":36,"investigatorFullName":34,"investigatorTitle":64,"investigatorAffiliation":5,"oldNameTitle":31,"oldOrganization":31},"MD. Head of Nephrology","100556147","impact-of-nicotinamide-riboside-nr-on-kidney-function-in-patients-undergoing-cardiac-surgery-100556147",false,"NCT06521307","Impact of Nicotinamide Riboside (NR) on Kidney Function in Patients Undergoing Cardiac Surgery","Impact of Nicotinamide Riboside (NR) on Kidney Function in Patients Undergoing Cardiac Surgery.A Randomized Controlled Pilot Study","AKI-RCT","Inclusion Criteria:\n\n* Heart valve replacement surgery\n* Sign of informed consent\n\nExclusion Criteria:\n\n* Allergy to any of the components\n* Platelet count less than 100,000\n* Weight less than 50Kg or over 100Kg\n* Any type of infectious disease (e. g, Endocarditis)\n* GFR less or equal to 15ml\u002Fmin\u002Fm2 or with renal replacement therapy\n* IV or oral contrast medium 72 hrs prior recruitment\n* LRA 7 days prior to surgery","ALL","18 Years",{"count":76,"type":77},100,"ESTIMATED","INTERVENTIONAL",[80],"NA","Acute kidney injury (AKI) associated with cardiac surgery is the most important complication in adult patients undergoing open heart surgery and is associated with increased mortality and morbidity. In patients in intensive care units, it is the second most common type of AKI after AKI secondary to sepsis. There is currently no specific treatment for AKI. Supportive measures include renal support therapy for patients with severe AKI, and mortality in this subgroup of patients exceeds 50%. Increasing NAD+ with niacinamide has been shown to prevent various etiologies of experimental AKI in mice, and an early pilot study has shown both increased NAD levels following administration of nicotinamide riboside with pterostilbene NPRT and the safety of niacinamide in patients undergoing cardiac surgery.",[83,84],"Acute Kidney Injury","Cardiac Valve Disease",[86,87,88,89,90,91,92,93,94],"Nicotinamide Riboside","NAD+","NADH","SIRT1","AKI","Cardiac surgery","TIMP-2","IGFBP7","NGAL","NOT_YET_RECRUITING","2024-07-24",{"date":98,"type":99},"2024-07-25","ACTUAL",{"date":96,"type":77},{"date":102,"type":77},"2026-07-24",{"name":5,"class":6},1]